Press Releases

BIOMS MEDICAL ANNOUNCES APPOINTMENTS TO BOARD OF DIRECTORS

Edmonton, Alberta, November 17, 2005 - BioMS Medical Corp (TSX: MS), a leading developer of products for the treatment of multiple sclerosis (MS), is pleased to announce the appointment of Mr. Bryan McKnight to the Company’s Board of Directors and Chair of the Audit Committee and Mr. Gordon Politeski as an advisor to the Board pending his nomination as a Director at the Company’s next annual meeting of shareholders.

In addition, Dr. Kjell Stenberg, currently a Director of BioMS Medical, will assume the newly created position of Chief Operating Officer of the Company, effective immediately.

“As we advance our lead drug for the treatment of MS through pivotal trials, it is important that we continue to strengthen our board and management team with seasoned professionals experienced in drug development, the capital markets and corporate governance,” said Kevin Giese, President of BioMS Medical. “We are delighted to welcome Mr. McKnight and Mr. Politeski to BioMS Medical and pleased that Dr. Stenberg will play an expanded role in driving our drug development programs.”

Bryan McKnight, FCA
Mr. McKnight brings strong public accounting and governance experience to the Board and Audit Committee. Mr. McKnight retired in 2003, after 27 years as a partner with KPMG LLP, including eight years as Managing Partner, Vancouver. He also served on KPMG's Operating and Management Committees and Board of Directors. During his public accounting career, Mr. McKnight worked with the boards and audit committees of many public companies and served on the boards of a number of community and charitable organizations. Mr. McKnight is currently a director of two other TSX listed public companies, Great Canadian Gaming Corporation and Extreme CCTV Inc.

Gordon Politeski
Mr. Politeski brings extensive international biotech development experience to BioMS Medical. He was the founding President and Chief Executive Officer of Biomira, Inc., a cancer diagnostics and therapy company, and one of Canada’s first publicly traded biotechnology companies. He also served as Director of the Pharmaceutical Group at Pharmacia Canada, Canadian President and General Manager for US-based Allergan Pharmaceuticals, a world leader in ophthalmology and the developer of Botox®, and was seven years on the board of AMEX listed Genetronics (now Inovio). Mr. Politeski is currently the Chairman of Novation Pharmaceuticals Inc., a private biotech company developing novel drugs to modulate messenger RNA in the treatment of various diseases.

Kjell Stenberg, Ph.D.
Dr. Stenberg has been on the Board of BioMS Medical since 2002 and brings strong pharmaceutical development experience to the newly created role of Chief Operating Officer. For 15 years, Dr. Stenberg held senior research and management positions at Astra and AstraZeneca, where his responsibilities included directing research in multiple sclerosis, management of international development teams, and being the director of external alliances for the development of products related to the Central Nervous System (which included MS). Dr. Stenberg gained biotech development experience as the founding CEO of Combio, an institutionally-funded biotech company based in Denmark, and was more recently in senior management at Orexo, a public biotech company based in Sweden.

This press release may contain forward-looking statements, which reflect the Corporation’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide (MBP8298) will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.